Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07566338
PHASE1

A Study of LY4302814 in Healthy Participants

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to assess how well LY4302814 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 6 months and will include at least one overnight stay in the clinical research unit (CRU) lasting up to approximately 9 days.

Official title: A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4302814 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2026-05-06

Completion Date

2027-08

Last Updated

2026-06-16

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

LY4302814

Administered SC

DRUG

LY4302814

Administered IV

DRUG

Placebo

Administered SC

DRUG

Placebo

Administered IV

Locations (2)

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States

Lilly Centre for Clinical Pharmacology

Singapore, Singapore